{"id":"https://openalex.org/W2464239697","doi":"https://doi.org/10.1200/jco.2016.34.7_suppl.19","title":"Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma following autologous stem cell transplant: A cost-effectiveness analysis updated with 5-year follow-up data from the pivotal trial.","display_name":"Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma following autologous stem cell transplant: A cost-effectiveness analysis updated with 5-year follow-up data from the pivotal trial.","alternate_titles":[],"publication_year":2016,"publication_date":"2016-03-01","ids":{"openalex":"https://openalex.org/W2464239697","doi":"https://doi.org/10.1200/jco.2016.34.7_suppl.19","mag":"2464239697"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2016.34.7_suppl.19","doi":"https://doi.org/10.1200/jco.2016.34.7_suppl.19","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2016.34.7_suppl.19","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2464239697"],"child_works_count":0,"type":"conference-abstract","is_traditional":false,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5046292225","display_name":"Christopher T. Parker","orcid":"https://orcid.org/0000-0002-0633-4592","observed_orcids":["https://orcid.org/0000-0002-0633-4592"]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Christopher Parker","raw_affiliation_strings":["ICON plc, Oxford, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"ICON plc, Oxford, United Kingdom","institution_ids":[]}]},{"author_position":"middle","author":{"id":null,"display_name":"Gemma Kay","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Gemma Kay","raw_affiliation_strings":["ICON plc, Oxford, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"ICON plc, Oxford, United Kingdom","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109896728","display_name":"Esprit Ma","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1290900354","display_name":"Tufts Medical Center","ror":"https://ror.org/002hsbm82","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1290900354"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Esprit Ma","raw_affiliation_strings":["Tufts Medical Centre, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Tufts Medical Centre, Boston, MA","institution_ids":["https://openalex.org/I1290900354"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5029103949","display_name":"Beth S. Woods","orcid":"https://orcid.org/0000-0002-7669-9415","observed_orcids":["https://orcid.org/0000-0002-7669-9415"]},"institutions":[{"id":"https://openalex.org/I52099693","display_name":"University of York","ror":"https://ror.org/04m01e293","country_code":"GB","type":"education","lineage":["https://openalex.org/I52099693"]}],"countries":["GB"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Beth Woods","raw_affiliation_strings":["Centre for Health Economics, University of York, York, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Centre for Health Economics, University of York, York, United Kingdom","institution_ids":["https://openalex.org/I52099693"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111945023","display_name":"James Eaton","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"James Eaton","raw_affiliation_strings":["ICON plc, Oxford, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"ICON plc, Oxford, United Kingdom","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5035950404","display_name":"Peter Sajosi","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405270001","display_name":"Takeda Oncology (United States)","ror":"https://ror.org/05vm7p871","country_code":"US","type":"company","lineage":["https://openalex.org/I4405270001"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Peter Sajosi","raw_affiliation_strings":["Millennium Pharmaceuticals Inc., Cambridge, MA, USA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Millennium Pharmaceuticals Inc., Cambridge, MA, USA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA","institution_ids":["https://openalex.org/I4405270001"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5024387394","display_name":"Andreas Engstr\u00f6m","orcid":"https://orcid.org/0000-0002-9740-5949","observed_orcids":["https://orcid.org/0000-0002-9740-5949"]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Andreas Engstrom","raw_affiliation_strings":["Takeda Pharma AB, Stockholm, Sweden"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Takeda Pharma AB, Stockholm, Sweden","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110696800","display_name":"Ross Selby","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210147578","display_name":"Takeda (United Kingdom)","ror":"https://ror.org/05c0v3585","country_code":"GB","type":"company","lineage":["https://openalex.org/I4210147578","https://openalex.org/I44892455"]}],"countries":["GB"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Ross Selby","raw_affiliation_strings":["Takeda UK Ltd., Bucks, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Takeda UK Ltd., Bucks, United Kingdom","institution_ids":["https://openalex.org/I4210147578"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5060990126","display_name":"Eugene Benson","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210147578","display_name":"Takeda (United Kingdom)","ror":"https://ror.org/05c0v3585","country_code":"GB","type":"company","lineage":["https://openalex.org/I4210147578","https://openalex.org/I44892455"]}],"countries":["GB"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Eugene Benson","raw_affiliation_strings":["Takeda UK Ltd., Bucks, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Takeda UK Ltd., Bucks, United Kingdom","institution_ids":["https://openalex.org/I4210147578"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5053769681","display_name":"Jeremy Teasell","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I99319750","display_name":"Seagen (United States)","ror":"https://ror.org/01vwesc15","country_code":"US","type":"company","lineage":["https://openalex.org/I99319750"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Jeremy Teasell","raw_affiliation_strings":["Seattle Genetics, Inc., Bothell, WA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Seattle Genetics, Inc., Bothell, WA","institution_ids":["https://openalex.org/I99319750"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5037707751","display_name":"Akshara Richhariya","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I99319750","display_name":"Seagen (United States)","ror":"https://ror.org/01vwesc15","country_code":"US","type":"company","lineage":["https://openalex.org/I99319750"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Akshara Richhariya","raw_affiliation_strings":["Seattle Genetics, Inc., Bothell, WA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Seattle Genetics, Inc., Bothell, WA","institution_ids":["https://openalex.org/I99319750"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5019479654","display_name":"Andrew H. Briggs","orcid":"https://orcid.org/0000-0002-0777-1997","observed_orcids":["https://orcid.org/0000-0002-0777-1997"]},"institutions":[{"id":"https://openalex.org/I7882870","display_name":"University of Glasgow","ror":"https://ror.org/00vtgdb53","country_code":"GB","type":"education","lineage":["https://openalex.org/I7882870"]}],"countries":["GB"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Andrew Briggs","raw_affiliation_strings":["University of Glasgow, Glasgow, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Glasgow, Glasgow, United Kingdom","institution_ids":["https://openalex.org/I7882870"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5108417203","display_name":"Vijayveer Bonthapally","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405270001","display_name":"Takeda Oncology (United States)","ror":"https://ror.org/05vm7p871","country_code":"US","type":"company","lineage":["https://openalex.org/I4405270001"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Vijayveer Bonthapally","raw_affiliation_strings":["Millennium Pharmaceuticals, Inc., Cambridge, MA, USA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Millennium Pharmaceuticals, Inc., Cambridge, MA, USA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA","institution_ids":["https://openalex.org/I4405270001"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":6,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":1,"reviewed_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"34","issue":"7_suppl","first_page":"19","last_page":"19"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10804","display_name":"Health Systems, Economic Evaluations, Quality of Life","score":0.9775000214576721,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},"topics":[{"id":"https://openalex.org/T10804","display_name":"Health Systems, Economic Evaluations, Quality of Life","score":0.9775000214576721,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},{"id":"https://openalex.org/T10185","display_name":"Lymphoma Diagnosis and Treatment","score":0.016899999231100082,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12708","display_name":"Economic and Financial Impacts of Cancer","score":0.0008999999845400453,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/brentuximab-vedotin","display_name":"brentuximab vedotin","score":1.0},{"id":"https://openalex.org/keywords/relapsed-refractory-hodgkin-lymphoma","display_name":"relapsed/refractory Hodgkin lymphoma","score":0.9869999885559082},{"id":"https://openalex.org/keywords/autologous-stem-cell-transplantation","display_name":"autologous stem cell transplantation","score":0.9909999966621399},{"id":"https://openalex.org/keywords/cost-effectiveness","display_name":"cost-effectiveness","score":0.9869999885559082},{"id":"https://openalex.org/keywords/incremental-cost-effectiveness-ratio","display_name":"incremental cost-effectiveness ratio","score":0.9440000057220459},{"id":"https://openalex.org/keywords/quality-adjusted-life-years","display_name":"quality-adjusted life years","score":0.9010000228881836},{"id":"https://openalex.org/keywords/partitioned-survival-model","display_name":"partitioned survival model","score":0.7730000019073486},{"id":"https://openalex.org/keywords/post-progression-survival","display_name":"post-progression survival","score":0.7129999995231628}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.891474723815918},{"id":"https://openalex.org/C2778191690","wikidata":"https://www.wikidata.org/wiki/Q422324","display_name":"Brentuximab vedotin","level":4,"score":0.8656109571456909},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.6524972915649414},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.628015398979187},{"id":"https://openalex.org/C2779050716","wikidata":"https://www.wikidata.org/wiki/Q4826373","display_name":"Autologous stem-cell transplantation","level":3,"score":0.5384597182273865},{"id":"https://openalex.org/C2911091166","wikidata":"https://www.wikidata.org/wiki/Q106419912","display_name":"Transplantation","level":2,"score":0.506639301776886},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.4663032591342926},{"id":"https://openalex.org/C2780739268","wikidata":"https://www.wikidata.org/wiki/Q2112244","display_name":"Progression-free survival","level":3,"score":0.4120372533798218},{"id":"https://openalex.org/C2779338263","wikidata":"https://www.wikidata.org/wiki/Q208414","display_name":"Lymphoma","level":2,"score":0.3340514302253723},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.3290829658508301},{"id":"https://openalex.org/C2992779791","wikidata":"https://www.wikidata.org/wiki/Q209369","display_name":"Hodgkin lymphoma","level":3,"score":0.2104930877685547}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2016.34.7_suppl.19","doi":"https://doi.org/10.1200/jco.2016.34.7_suppl.19","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2016.34.7_suppl.19","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":0.9537000060081482,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2481006301","https://openalex.org/W2596233600","https://openalex.org/W2980927938","https://openalex.org/W2028034612","https://openalex.org/W2592310779","https://openalex.org/W2545221124","https://openalex.org/W15172654","https://openalex.org/W4399388211","https://openalex.org/W4381105079","https://openalex.org/W4386347063"],"abstract_inverted_index":{"19":[0],"Background:":[1],"In":[2],"2015,":[3],"the":[4,41,51,75,83,144,154,169,185,188,196,212,224,236,248,264,267,273],"Scottish":[5,95],"Medicines":[6],"Consortium":[7],"(SMC)":[8],"made":[9],"a":[10,94,100,294],"positive":[11],"recommandation":[12],"for":[13,56,136,200,220,251,283,298],"brentuximab":[14,57],"vedotin":[15,58],"(BV)":[16],"in":[17,147,218,235,253,266,278],"patients":[18,254],"with":[19,60,78,122,153,166,255],"relapsed":[20],"or":[21,120],"refractory":[22],"(R/R)":[23],"Hodgkin":[24],"lymphoma":[25],"(HL)":[26],"who":[27],"have":[28],"received":[29],"autologous":[30],"stem":[31,126],"cell":[32,127],"transplantation":[33],"(ASCT)":[34],"based":[35,140],"on":[36,141],"3-year":[37],"follow-up":[38,80,193,261],"data":[39,81,142,194],"from":[40,82,143,202,232],"pivotal":[42,84,145],"phase":[43],"2":[44],"single-arm":[45],"trial":[46,146],"(SG035-0003;":[47],"NCT00848926).":[48],"At":[49],"3-years,":[50],"incremental":[52],"cost-effectiveness":[53,76,249],"ratio":[54],"(ICER)":[55],"compared":[59],"chemotherapy":[61],"+/-":[62],"radiotherapy":[63],"(C/R)":[64],"was":[65,91,157,228],"\u00a343,731":[66,203],"per":[67,206],"quality-adjusted":[68],"life":[69],"year":[70],"(QALY).":[71],"This":[72,244],"study":[73],"re-evaluated":[74],"analysis":[77],"5-year":[79,192,260],"trial.":[85],"Methods:":[86],"A":[87,150],"partitioned":[88],"survival":[89,109,134,161],"model":[90],"developed":[92],"using":[93,159],"health":[96,104],"system":[97],"perspective":[98],"over":[99],"lifetime":[101],"time-horizon.":[102],"Three":[103],"states":[105],"were":[106,118,138,164,181],"evaluated:":[107],"progression-free":[108],"(PFS),":[110],"post-progression":[111],"survival,":[112],"and":[113,132,174,177,210,271],"death.":[114],"The":[115,191,216,259],"relevant":[116],"comparators":[117,156],"C/R,":[119],"C/R":[121,209],"intent":[123],"to":[124,183,204,280],"allogeneic":[125],"transplantation.":[128],"Clinical":[129],"outcomes":[130,270],"(PFS":[131],"overall":[133],"[OS])":[135],"BV":[137,201,221,252,290],"estimated":[139],"102":[148],"patients.":[149],"na\u00efve":[151],"comparison":[152,279],"specified":[155],"conducted":[158,182],"published":[160],"data.":[162],"ICERs":[163],"calculated":[165],"measures":[167],"of":[168,187,214,238],"clinical":[170,241],"outcomes,":[171],"direct":[172],"costs":[173],"QALYs.":[175],"Deterministic":[176],"probabilistic":[178],"sensitivity":[179,226],"analyses":[180,227],"evaluate":[184],"robustness":[186],"model.":[189],"Results:":[190],"reduced":[195,230,233,263,272],"base":[197],"case":[198],"ICER":[199,219],"\u00a338,769":[205],"QALY":[207],"versus":[208],"increased":[211],"probability":[213],"cost-effectiveness.":[215],"variation":[217],"generated":[222],"by":[223,287],"deterministic":[225],"also":[229],"resulting":[231],"uncertainty":[234,265],"estimation":[237],"long":[239,268],"term":[240,269],"outcomes.":[242],"Conclusions:":[243],"update":[245],"has":[246,262],"strengthened":[247],"evidence":[250],"R/R":[256],"HL":[257],"post-ASCT.":[258],"ICER,":[274],"which":[275],"is":[276],"low":[277],"other":[281],"treatments":[282],"orphan":[284],"diseases":[285],"approved":[286],"UK":[288],"agencies.":[289],"may":[291],"therefore":[292],"represent":[293],"cost-effective":[295],"treatment":[296],"option":[297],"this":[299],"patient":[300],"group.":[301]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2464239697","counts_by_year":[{"year":2018,"cited_by_count":1}],"updated_date":"2026-09-29T14:09:16.559479","created_date":"2016-07-22T00:00:00"}
